
Opinion|Videos|April 11, 2025
Key Limitations of MAIC Analyses
Author(s)Arun Azad, PhD, MBBS
A panelist discusses how Matching-Adjusted Indirect Comparison (MAIC) analyses are limited by potential unmeasured confounding factors, small effective sample sizes after matching, and reliance on published aggregate data, which should be carefully considered when interpreting findings as complementary rather than definitive evidence for treatment decisions.
Advertisement
Episodes in this series

Summary for Physicians: Limitations of MAIC Analyses
MAIC analyses, although useful, have several important methodological limitations:
- Potential unmeasured confounding factors may still bias results despite matching procedures.
- Effective sample sizes are often substantially reduced after matching, limiting statistical power.
- Reliance on aggregate published data rather than individual patient data introduces additional uncertainty.
When reviewing MAIC analyses, consider these findings as complementary evidence rather than definitive proof for treatment decisions. These analyses should be interpreted within the broader context of available clinical evidence.
Advertisement
Related to this article

Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.

The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.

John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.

Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
3
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5



